ETF Holdings Breakdown of AXSM

News associated with AXSM

Janney Montgomery Scott LLC Has $1.74 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Janney Montgomery Scott LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 8.6% in the 1st quarter, HoldingsChannel reports. The fund owned 14,923 shares of the company’s stock after buying an additional 1,178 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Axsome Therapeutics were worth $1,740,000 at the end […] - 2025-06-27 07:26:52

AXSM Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Axsome Therapeutics Inc (Symbol: AXSM) crossed below their 200 day moving average of $102.28, changing hands as low as $101.01 per share. Axsome Therapeutics Inc shares are currently trading down about 1.9% on the day. The chart below shows the - 2025-06-16 15:41:26

GAMMA Investing LLC Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

GAMMA Investing LLC increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 38,571.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,043 shares of the company’s stock after buying an additional 21,986 shares during the quarter. GAMMA Investing […] - 2025-06-13 08:14:47

Rhumbline Advisers Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Rhumbline Advisers boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 6.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,760 shares of the company’s stock after acquiring an additional 3,515 shares during the quarter. Rhumbline Advisers’ holdings in Axsome Therapeutics […] - 2025-06-12 08:31:01

HC Wainwright Reiterates “Buy” Rating for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $180.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 66.54% from the stock’s previous close. Several other […] - 2025-06-12 05:18:55

Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective decreased by Needham & Company LLC from $153.00 to $150.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 36.48% from the […] - 2025-06-11 05:44:51

Nuveen Asset Management LLC Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Nuveen Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 118.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 221,202 shares of the company’s stock after acquiring an additional 119,780 shares during the period. Nuveen Asset Management LLC’s holdings in Axsome Therapeutics were worth $18,716,000 as of its […] - 2025-05-25 09:03:20

Captrust Financial Advisors Sells 2,769 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors decreased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 48.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,953 shares of the company’s stock after selling 2,769 shares during the period. Captrust Financial Advisors’ holdings in Axsome Therapeutics […] - 2025-05-22 07:47:00

Comerica Bank Sells 3,570 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Comerica Bank trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 32.6% during the 4th quarter, HoldingsChannel reports. The firm owned 7,374 shares of the company’s stock after selling 3,570 shares during the quarter. Comerica Bank’s holdings in Axsome Therapeutics were worth $624,000 at the end of the most recent reporting period. […] - 2025-05-15 07:52:49

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $162.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Robert W. Baird from $160.00 to $162.00 in a report released on Tuesday, Marketbeat reports. Robert W. Baird currently has an outperform rating on the stock. Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” […] - 2025-05-09 06:56:43

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,228 shares of the company’s stock after acquiring an additional 3,366 shares during the period. Price T Rowe Associates […] - 2025-05-07 08:50:49

Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% After Earnings Beat

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price was up 5.6% during trading on Monday following a better than expected earnings announcement. The stock traded as high as $117.60 and last traded at $118.54. Approximately 231,459 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 683,737 […] - 2025-05-07 05:24:42

Legal & General Group Plc Decreases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Legal & General Group Plc cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,370 shares of the company’s stock after selling 503 shares during the period. Legal […] - 2025-04-24 08:06:51

Raymond James Financial Inc. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Raymond James Financial Inc. bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 174,586 shares of the company’s stock, valued at approximately $14,771,000. A number of […] - 2025-04-22 08:10:57

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. boosted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,852 shares of the company’s stock after purchasing an additional 162 shares […] - 2025-04-21 07:56:55

Russell Investments Group Ltd. Boosts Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Russell Investments Group Ltd. boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1,815.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,437 shares of the company’s stock after buying an additional 18,422 shares during the quarter. Russell Investments Group Ltd.’s holdings in Axsome Therapeutics were worth $1,645,000 as of its […] - 2025-04-20 08:20:47

Jefferies Financial Group Initiates Coverage on Axsome Therapeutics (NASDAQ:AXSM)

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $200.00 price objective on the stock. AXSM has been the topic of several other reports. William Blair reaffirmed an “outperform” rating […] - 2025-04-08 05:40:49

Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Schroder Investment Management Group decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 58.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,142 shares of the company’s stock after selling 34,158 shares during the quarter. Schroder […] - 2025-04-07 08:13:00

Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.64

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the […] - 2025-04-03 05:50:59

KLP Kapitalforvaltning AS Makes New $745,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,800 shares of the company’s stock, valued at approximately $745,000. Other institutional investors and hedge funds have […] - 2025-04-02 08:12:56

Cibc World Markets Corp Purchases Shares of 3,445 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Cibc World Markets Corp acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,445 shares of the company’s stock, valued at approximately $291,000. A number of other hedge funds and […] - 2025-03-25 08:16:52

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of “Buy” from Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Fifteen equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock […] - 2025-03-06 07:33:01

Axsome Settles Patent Litigation With Hikma Related To Sunosi - Quick Facts

(RTTNews) - Axsome Therapeutics (AXSM) has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. resolving patent litigation related to Axsomes product Sunosi or solriamfetol. Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on - 2025-03-05 12:42:10

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from $132.00 to $160.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 27.42% from […] - 2025-03-05 06:32:48

Handelsbanken Fonder AB Sells 500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Handelsbanken Fonder AB lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,800 shares of the company’s stock after selling 500 shares during the quarter. Handelsbanken Fonder AB’s holdings in […] - 2025-02-28 09:25:09

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Lowered by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.9% during the 4th quarter, HoldingsChannel reports. The firm owned 21,990 shares of the company’s stock after selling 421 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Axsome Therapeutics […] - 2025-02-25 09:20:52

Axsome Therapeutics (NASDAQ:AXSM) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $153.00 target price on the stock. Other analysts also recently issued research reports about the stock. Needham & Company LLC increased their target price on […] - 2025-02-20 09:05:34

Axsome Therapeutics (NASDAQ:AXSM) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Tuesday,RTT News reports. Other equities research analysts have also recently issued reports about the company. Bank of America lifted their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” […] - 2025-02-19 08:46:48

Wells Fargo & Company Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo & Company from $140.00 to $160.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 21.51% […] - 2025-02-14 09:35:09

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Mizuho Analyst Says

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price raised by research analysts at Mizuho from $137.00 to $195.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target suggests a potential upside of 48.23% from the company’s previous close. Other equities analysts […] - 2025-02-13 08:52:53

AXSM institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	20,795	USD 2,132,943
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	7,264	USD 745,068
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	47,573	USD 4,879,563
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	24,570	USD 2,520,145
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	24,570	USD 2,520,145
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	146	USD 14,975
Total =		124,918	USD 12,812,839

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer